Head to Head Review: Nutriband (NASDAQ:NTRB) and Jin Medical International (NASDAQ:ZJYL)

Nutriband (NASDAQ:NTRB) and Jin Medical International (NASDAQ:ZJYL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Insider & Institutional Ownership

19.7% of Nutriband shares are owned by institutional investors. 43.2% of Nutriband shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Nutriband has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Comparatively, Jin Medical International has a beta of 15.77, indicating that its stock price is 1,477% more volatile than the S&P 500.

Profitability

This table compares Nutriband and Jin Medical International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nutriband	-401.39%	-66.60%	-56.41%
Jin Medical International	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent recommendations for Nutriband and Jin Medical International, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	0	0	0	0	N/A
Jin Medical International	0	0	0	0	N/A

Earnings and Valuation

This table compares Nutriband and Jin Medical International”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutriband	$1.80 million	40.99	-$5.49 million	($0.77)	-8.70
Jin Medical International	$20.13 million	21.33	$2.88 million	N/A	N/A

Jin Medical International has higher revenue and earnings than Nutriband.

Summary

Jin Medical International beats Nutriband on 6 of the 9 factors compared between the two stocks.

About Nutriband

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

About Jin Medical International

Jin Medical International Ltd. engages in the design, development, manufacturing, and sale of wheelchair and other living aids products for people with disabilities or impaired mobility in China and internationally. It also offers oxygen concentrators and bathing machines. The company was founded in 2006 and is based in Changzhou, China. Jin Medical International Ltd. is a subsidiary of Jolly Harmony Enterprises Limited.